Sionna Therapeutics Q3 2026: Miss, Layoffs, and a 2029 Cash Runway

Sionna Therapeutics reported a GAAP loss of $0.72 per share for the third quarter of 2026, missing the consensus estimate of roughly $0.68 by 6.27%. The wider-than-expected loss reflects the direct financial consequence of a painful restructuring: an approximately 46% workforce reduction carried out in September 2026 pushed charges into both research and development and general and administrative expenses.

R&D expense rose to $22.02 million from $16.04 million in the same quarter a year earlier, while G&A climbed to $12.79 million from $7.76 million. Both lines were inflated by personnel costs, stock-based compensation, and the restructuring charges themselves. Revenue was zero, consistent with Sionna's status as a clinical-stage company with no commercialized products.

The cuts were designed to extend the company's financial runway, and on that measure the strategy appears to be working. Cash, cash equivalents, and marketable securities stood at $249.8 million at quarter-end, down from $310.3 million at year-end 2025, with management guiding that balance to fund operations into the second half of 2029. That runway is notably longer than the company's $161 million market capitalization, a gap that investors in clinical-stage biotechs often watch closely.

The capital is focused on a single program: the SION-451 plus SION-2222 dual combination, which Sionna describes as an NBD1-anchored approach to correcting the CFTR protein defect underlying cystic fibrosis. The company plans to initiate its AscenSION CF Phase 2 proof-of-concept trial of that combination in the first quarter of 2027. The trial will enroll CF patients homozygous for the F508del mutation who switch from Trikafta, assessing sweat chloride reduction, safety, and pharmacokinetics over 28 days.

The pivot to this dual combination follows the failure of an earlier program: the PreciSION CF Phase 2a trial of SION-719 as an add-on to standard of care missed its key activity endpoint, and that candidate is not advancing in that setting. A post hoc analysis excluding three non-adherent participants did show a mean placebo-adjusted sweat chloride reduction of up to 8.6 mmol/L, but management has characterized those findings as exploratory support for the broader NBD1 stabilizer approach rather than a basis for reviving SION-719.